My first question is why did it take the BSI body for CE Mark more than 14months to simply say that they needed more information.
Why didn't Oncosil simply state in their asx announcement that their submission for CE Mark approval was rejected in its current form without the test results of the first 20 patients.
They simply state that "they are pleased that the CE Mark is granted" provided that they undertake further testing and then that data has to be reviewed.
I don't know what kind of spin they can place on it tomorrow. Unless I am reading it all wrong and there is good news in the release.
Either way sales won't be coming into the tilt until atleast 2018 and that is predicated on good results. Which I am still positive about. But what does the time delay do for their cash flow going into the future. They will still need another $5-10M surely.
Good luck all. The question now for the retail holders is do you stay and remain patient or move on.
OSL Price at posting:
9.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)